Geoffrey C. Gillespie Sells 767 Shares of Orthofix Medical Inc. (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CAO Geoffrey C. Gillespie sold 767 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $17.79, for a total value of $13,644.93. Following the completion of the sale, the chief accounting officer now owns 39,323 shares of the company’s stock, valued at $699,556.17. The trade was a 1.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Orthofix Medical Trading Down 3.0 %

Shares of Orthofix Medical stock opened at $18.47 on Friday. The company’s fifty day simple moving average is $18.03 and its two-hundred day simple moving average is $17.15. Orthofix Medical Inc. has a 12-month low of $12.08 and a 12-month high of $20.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11.

Orthofix Medical (NASDAQ:OFIX) last posted its earnings results on Thursday, November 7th. The medical device company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.57). The business had revenue of $196.61 million during the quarter, compared to the consensus estimate of $196.60 million. Orthofix Medical had a negative return on equity of 21.25% and a negative net margin of 15.18%. During the same period in the previous year, the business earned ($0.77) earnings per share. Sell-side analysts predict that Orthofix Medical Inc. will post -2.81 EPS for the current year.

Analysts Set New Price Targets

OFIX has been the subject of a number of recent research reports. Stifel Nicolaus upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $18.00 to $24.00 in a report on Friday, November 8th. Roth Mkm reaffirmed a “buy” rating and set a $22.00 price objective (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Canaccord Genuity Group started coverage on Orthofix Medical in a report on Wednesday, January 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Finally, StockNews.com upgraded Orthofix Medical from a “hold” rating to a “buy” rating in a report on Friday, January 31st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Institutional Investors Weigh In On Orthofix Medical

A number of large investors have recently made changes to their positions in OFIX. Sei Investments Co. lifted its stake in Orthofix Medical by 24.6% in the second quarter. Sei Investments Co. now owns 46,195 shares of the medical device company’s stock worth $613,000 after acquiring an additional 9,114 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Orthofix Medical in the 2nd quarter valued at approximately $405,000. AQR Capital Management LLC grew its stake in Orthofix Medical by 4.4% in the second quarter. AQR Capital Management LLC now owns 31,863 shares of the medical device company’s stock worth $423,000 after purchasing an additional 1,336 shares during the period. SG Americas Securities LLC raised its holdings in Orthofix Medical by 74.0% in the third quarter. SG Americas Securities LLC now owns 17,117 shares of the medical device company’s stock worth $267,000 after purchasing an additional 7,278 shares in the last quarter. Finally, Inspire Investing LLC bought a new position in Orthofix Medical in the third quarter worth $417,000. 89.76% of the stock is currently owned by institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.